Table 3.

Change in levels of analytes stratified by percent weight loss compared with controls, by randomization arm, where missing data on weight were imputed using LOCF

Analyte andDietExerciseDiet + Exercise
weight changeBaseline12 monthsAbs. changeBaseline12 monthsAbs. changeBaseline12 monthsAbs. change
categoriesanGM (95% CI)nGM (95% CI)(%)bPcnGM (95% CI)nGM (95% CI)(%)bPcnGM (95% CI)nGM (95% CI)(%)bPc
Oxidized LDL (U/L)
Control8797.22(89.33–105.8)8799.41 (91.97–107.4)2.19(2.3)8797.22 (89.33–105.8)8799.41(91.97–107.4)2.19(2.3)8797.22(89.33–105.8)8799.41(91.97–107.4)2.19(2.3)
No change/gained weight23112.0 (98.38–127.6)23107.6 (94.24–122.9)−4.41(−3.9)0.2641106.4 (96.28–117.6)41109.1(98.19–121.2)2.67(2.5)0.7812106.2(89.22–126.3)12108.8(88.56–133.8)2.70(2.5)0.93
Lost <5%19103.3 (88.90–120.0)1997.35 (80.90–117.1)−5.93 (−5.7)0.2846104.7 (91.52–119.7)4699.22(88.98–110.6)−5.43(−5.2)0.4314116.5(98.72–137.5)14107.4(89.56–128.7)−9.16(−7.9)0.21
Lost ≥5%76105.7 (97.93–114.1)7698.77 (91.52–106.6)−6.95 (−6.6)0.082994.51 (81.43–109.7)2994.26(81.38–109.2)−0.25(−0.3)0.929097.96(91.80–104.5)9089.44(83.83–95.43)−8.52(−8.7)0.02
Ptrendd0.060.620.02
FOP (FI milliunits/mL)
Control8739.7 (35.1–44.9)8737.4 (35.0–39.9)−2.3 (−5.8)8739.7(35.1–44.9)8737.4(35.0–39.9)−2.3(−5.8)8739.7(35.1–44.9)8737.4(35.1–39.9)−2.3(−5.8)
No change/gained weight2341.5 (30.2–57.1)2342.7 (31.3–58.4)1.2 (2.9)0.154146.3(35.1–61.1)4143.9(33.1–58.4)−2.3(−5.1)0.901237.6(33.0–42.8)1238.6(33.2–44.9)1.0(2.7)0.12
Lost <5%1935.3 (31.5–39.5)1936.8 (32.8–41.2)1.5 (4.2)0.054643.2(35.6–52.3)4640.8(33.7–49.5)−2.3(−5.4)0.981432.7(28.1–38.1)1438.0(35.2–41.1)5.3(16.3)0.003
Lost ≥5%7635.0 (32.8–37.4)7642.6 (39.9–45.4)7.5 (21.5)<0.00012943.4(35.5–53.0)2942.0(37.0–47.7)−1.3(−3.1)0.889040.7(36.9–44.9)9048.7(43.3–54.8)8.0(19.7)0.0001
Ptrendd<0.00010.93<0.0001
F2-Isoprostanes(pg/mL)
Control8356.23 (50.71–62.36)8354.55 (49.15–60.54)−1.68 (−3.0)8356.23(50.71–62.36)8354.55(49.15–60.54)−1.68(−3.0)8356.23(50.71–62.36)8354.55(49.15–60.54)−1.68(−3.0)
No change/gained weight1966.94 (55.02–81.45)1957.39 (36.49–90.26)−9.55 (−14.3)0.543962.35(54.88–70.85)3959.28(52.16–67.36)−3.08(−4.9)0.60962.87(45.25–87.35)968.38(47.21–99.04)5.508(8.8)0.06
Lost <5%1656.17 (43.95–71.80)1647.43 (38.00–59.19)−8.75 (−15.6)0.154260.80(51.51–71.77)4250.80(42.06–61.35)−10.0(−16.5)0.051359.90(47.15–76.10)1356.69(40.90–78.57)−3.22(−5.4)0.72
Lost ≥5%7155.36 (48.89–62.69)7140.80 (36.00–46.23)−14.6 (−26.3)<0.00012757.44(46.73–70.61)2743.64(34.80–54.72)−13.8(−24.0)0.00028652.44(46.37–59.32)8637.44(33.72–41.57)−15.0(−28.6)<0.0001
Ptrendd<0.00010.0002<0.0001
  • Abbreviations: CI, confidence interval; GM, geometric mean.

  • aChange at 12 months from baseline.

  • bAnalyses stratified by weight loss percentage and using all available data (participants randomized to intervention arms with missing 12-month weight were classified as having no change/gained).

  • cP value obtained from GEE model comparing the difference in change of the biomarkers from baseline to 12-month in intervention group versus control within strata of percent weight loss, adjusted for age, baseline BMI (<30 kg/m2, ≥30 kg/m2), race/ethnicity (White, Black, and others), NSAID use, and statins use.

  • dP value obtained from GEE model testing the linear trend in the change of the biomarkers from baseline to 12-month from control through all levels of percent weight loss, adjusted for age, baseline BMI (<30 kg/m2, ≥30 kg/m2), race/ethnicity (White, Black, and others), NSAID use, and statins use.